Current Problems in Surgery
Volume 46, Issue 12 , Pages 944-1004 , December 2009

Breast Cancer in Premenopausal Women

  • John T. Vetto, MD

      Affiliations

    • Professor of Surgery, Division of Surgical Oncology, Director, Cutaneous Oncology Program, Oregon Health & Science University, Portland, Oregon
    • ,
  • Shiuh Wen Luoh, MD, PhD

      Affiliations

    • Assistant Professor of Medicine, Oregon Health & Science University, Portland, Oregon
    • ,
  • Arpana Naik, MD

      Affiliations

    • Assistant Professor of Surgery, Medical Director, Breast Center, Oregon Health & Science University, Portland, Oregon

References 

  1. Olson JS. Bathsheba's Breast: Women, Cancer, and History. In: Baltimore: Johns Hopkins University Press; 2002;p. 27–45
  2. Larson, Nancy History of Breast Cancer Treatment: Advances in Prevention, Detection, and Treatment Greatly Improve Outcomes. http://breastcancer.about.com/lw/Health-Medicine/Conditions-and-diseases/History-of-Breast-Cancer.htmAccessed May 5, 2009
  3. Fisher B. From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. Eur J Cancer. 1999;35:1963–1973
  4. World Health Organization. Fact Sheet 297: Cancer. www.who.int/mediacentre/factsheets/fs297/en/index.htmlAccessed May 5, 2009
  5. Reis LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER Cancer Statistics Review: 1975-2000. Bethesda, MD: National Cancer Institute; 2003;
  6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics 2008. CA Cancer J Clin. 2008;58:71–96
  7. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, et al. Catechol estrogen quinines as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta. 2006;1766:63–78
  8. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354:270–282
  9. Sieri S, Krogh V, Ferrari P, Berrino F, Pala V, Thiébaut AC, et al. Dietary fat and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr. 2008;88:1304–1312
  10. Allen NE, Beral V, Casabonne D, Kan SW, Reeves GK, Brown A, et al. Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst. 2009;101:296–305
  11. Dorjgochoo T, Shu XO, Li HL, Qian HZ, Yang G, Cai H, et al. Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer. 2009;124:2442–2449
  12. Rosenberg L, Zhang Y, Coogan PF, Strom BL, Palmer JR. A case-control study of oral contraceptive use and incident breast cancer. Am J Epidemiol. 2009;169:473–479
  13. Manson JE, Martin KA. Clinical practice (Post-menopausal hormone replacement therapy). N Engl J Med. 2001;345:34–40
  14. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of Estrogen plus progestin breast cancer and mammography in healthy post-menopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289:3243–3253
  15. Meisner ALW, Fekrazad MH, Royce ME. Breast disease: benign and malignant. Med Clin N Am. 2008;92:1115–1141
  16. Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol. 1996;122:135–140
  17. Gershoni-Baruch R, Dagan E, Fried G, Bruchim Bar-Sade R, Sverdlov-Shiri R, et al. Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer. Eur J Cancer. 2000;36:983–986
  18. Claus EB, Risch NJ, Thompson D. Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol. 1990;131:961–972
  19. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005;23:276–292
  20. Nahleh Z, Girnius S. Male breast cancer: a gender issue. Nat Clin Pract Oncol. 2006;3:428–437
  21. National Cancer Institute. Breast Cancer Risk Assessment Tool. http://www.cancer.gov/bcrisktoolAccessed April 4, 2009
  22. BayesMendel Lab. BRCAPRO. http://astor.som.jhmi.edu/BayesMendel/brcapro.htmlAccessed April 4, 2009
  23. Ozanne EM, Loberg A, Hughes S, Lawrence C, Drohan B, Semine A, et al. Identification and management of women at high risk for hereditary breast/ovarian cancer syndrome. Breast J. 2009;15:155–162
  24. Who Should Be Tested. http://www.tirgan.com/genetics/genwhotested.htmAccessed April 4, 2009
  25. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology (Genetic/familial high-risk assessment: breast and ovarian). Version 1.2008 http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdfAccessed April 4, 2009
  26. Petrucelli N, Daly M, Burke W, et al. BRCA1 and BRCA2 Hereditary Breast/Ovarian Cancer. Seattle: University of Washington; June 19, 2007;http://www.geneclinics.org/servlet/access?id=8888892&key=73D5C3k7FaQQ5&gry=INSERTGRY&fcn=y&fw=TwOh&filename=/glossary/profiles/brca1/details.htmlAccessed April 4, 2009
  27. Smith AW, Dougall AL, Posluszny DM, Somers TJ, Rubinstein WS, Baum A, et al. Psychological distress and quality of life associated with genetic testing for breast cancer risk. Psychooncology. 2008;17:767–773
  28. Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW. Early-onset breast cancer—histopathological and prognostic considerations. Br J Cancer. 1997;75:1318–1323
  29. Klauber-DeMore N. Tumor biology of breast cancer in young women. Breast Dis. 2005;23:9–15
  30. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol. 1994;12:888–894
  31. Walker RA, Lees E, Webb MB, Dearing SJ. Breast carcinomas occurring in young women (< 35 years) are different. Br J Cancer. 1996;74:1796–1800
  32. Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996;77:97–103
  33. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Orlando L, Ghisini R, et al. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol. 2006;17:1497–1503
  34. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009
  35. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–2826
  36. Calsa S, Hall P, Auer G, Bjöhle J, Klaar S, Kronenwett U, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006;8:R34
  37. Understanding Breast Cancer. http://www.komen.org/BreastCancer/DiagnosisAccessed March 25, 2009
  38. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;355:560–569
  39. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–2502
  40. Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med. 2006;12:537–544
  41. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Ocol. 2009;20:628–635
  42. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109:123–139
  43. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thürlimann B, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. Lancet. 2000;355:1869–1874
  44. Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002;13:273–279
  45. Anderson BO, Senie RT, Vetto JT, Wong GY, McCormick B, Borgen PI, et al. Improved survival in young women with breast cancer. Ann Surg Oncol. 1995;2:407–415
  46. Brinton LA, Sherman ME, Carreon JD, Anderson WF. Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst. 2008;100:1643–1648
  47. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109:1721–1728
  48. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009;113:357–370
  49. Duffy SW, Tabar L, Vitak B, Yen MF, Warwick J, Smith RA, et al. The Swedish Two-County Trial of mammographic screening: cluster randomization and end point evaluation. Ann Oncol. 2003;14:1196–1198
  50. Eastman P. NCI adopts new mammography screening guidelines for women. J Natl Cancer Inst. 1997;89:538–540
  51. ACS Guidelines for Breast Cancer Screening. http://www.acs.orgAccessed March 7, 2009
  52. The Susan G. Komen for the Cure Foundation (Early Detection and Screening: Clinical Breast Exam). http://www.komen.orgAccessed March 6, 2009
  53. Jimenez-Lee R, Oslak SG, Hedberg K, Vetto JT. Surgical outcomes of a breast cancer-screening program for low-income women. Arch Surg. 2003;138:884–890
  54. Vetto JT, Wheeler AJ, Toomey M, Schmidt KJ. Outcomes among women younger than age 40 in a state breast cancer screening program. Am J Surg. 2006;191:635–640
  55. Sarff M, Schmidt K, Vetto JT. Targeted breast cancer screening in women younger than 40: results from a statewide program. Am J Surg. 2008;195:626–630
  56. Humphrey LL, Helfand M, Chan BKS, Woolf SH. Breast cancer screening: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002;1375:347–360
  57. Kern KA. The delayed diagnosis of breast cancer: medico legal implications and risk prevention for surgeons. Breast Dis. 2001;12:145–158
  58. Kelemen LE, Pankratz VS, Sellers TA, Brandt KR, Wang A, Janney C, et al. Age-specific trends in mammographic density: the Minnesota Breast Cancer Family Study. Am J Epidemiol. 2008;167:1027–1036
  59. McGinnis LS, Menck HR, Eyre HJ, Bland KI, Scott-Corner CE, Morrow M, et al. National cancer data base survey of breast cancer management for patients from low income zip codes. Cancer. 2000;88:933–945
  60. Cohen MI, Mintxer RA, Matthies HJ, Bernstein JR. Mammography in women less than 40 years of age. Surg Gynecol Obstet. 1985;160:220–222
  61. Bobo JK, Lee NC, Thames SF. Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst. 2000;92:971–976
  62. Bobo JK, Lee N. Factors associated with accurate cancer detection during a clinical breast examination. Ann Epidemiol. 2000;10:463
  63. Barton MB, Harris R, Fletcher SW. Does this patient have breast cancer? (The screening clinical breast examination: should it be done? How?). JAMA. 1999;282:1270–1280
  64. Vetto JT, Petty JK, Dunn N, Prouser NC, Austin DF. Structured clinical breast examination (CBE) training results in objective improvement in CBE skills. J Cancer Educ. 2002;17:124–127
  65. Vetto JT, Pommier RF, Schmidt WA, Eppich H, Alexander PW. Diagnosis of palpable breast lesions in younger women by the modified triple test is accurate and cost-effective. Arch Surg. 1996;131:967–972
  66. Morris KT, Vetto JT, Petty JK, Lum SS, Schmidt WA, Toth-Fejel S, et al. A new score for the evaluation of palpable breast masses in women under age 40. Am J Surg. 2002;184:346–347
  67. MARIBS study group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005;365:1769–1778
  68. Kuhl CK, Schrading S, Weigel S, Nüssle-Kügele K, Sittek H, Arand B, et al. The “EVA” Trial: Evaluation of the efficacy of diagnostic methods (mammography, ultrasound, MRI) in the secondary and tertiary prevention of familial breast cancer (Preliminary results after the first half of the study period). Rofo. 2005;177:818–827
  69. Hayes DF, Kaplan W. evaluation of patients after primary therapy. In:  Harris JR,  Lippman M,  Morrow M,  Hellman S editor. Diseases of the Breast. Philadelphia: Lippincott-Raven; 1996;p. 634
  70. Chang SS, Giulliano AE. Early invasive breast cancer. In:  Khatri VP editors. Clinical Scenarios in Surgical Oncology. Philadelphia: Lippincott Williams & Wilkins; 2006;p. 225
  71. Pons F, Duch J, Fuster D. Breast cancer therapy: the role of PET-CT in decision making. Q J Nucl Med Mol Imaging. 2009;53:210–228
  72. Kruser TJ, Bradley KA, Bentzen SM, Anderson BM, Gondi V, Khuntia D, et al. The impact of hybrid PET-CT scan on overall oncologic management, with a focus on radiotherapy planning: a prospective, blinded study. Technol Cancer Res Treat. 2009;8:149–158
  73. Duch J, Fuster D, Muñoz M, Fernández PL, Paredes P, Fontanillas M, et al. (18)F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging. 2009 Mar 27;[Epub ahead of print]
  74. Toy EC, Liu TH, Campbell AR. Case Files: Surgery. In: New York: Lange Medical Books, McGraw-Hill; 2007;p. 18
  75. Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble B, Giuliano A, et al. Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin. 2002;52:277–300
  76. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–1241
  77. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–1232
  78. van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92:1143–1150
  79. van Nes JG, van de Velde CJ. The preferred treatment for young women with breast cancer–mastectomy versus breast conservation. Breast. 2006;15(Suppl2):S3–S10
  80. Kurtz JM, Jacquemier J, Amalric R, Brandone H, Ayme Y, Hans D, et al. Why are local recurrences after breast-conserving therapy more frequent in younger patients?. J Clin Oncol. 1990;8:591–598
  81. Kurtz JM, Spitalier JM, Amalric R, Brandone H, Ayme Y, Bressac C, et al. Mammary recurrences in women younger than forty. Int J Radiat Oncol Biol Phys. 1988;15:271–276
  82. Elkhuizen PH, van de Vijver MJ, Hermans J, Zonderland HM, van de Velde CJ, Leer JW. Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys. 1998;40:859–867
  83. Kim SH, Simkovich-Heerdt A, Tran KN, Maclean B, Borgen PI. Women 35 years of age or younger have higher locoregional relapse rates after undergoing breast conservation therapy. J Am Coll Surg. 1998;187:1–8
  84. Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19:1688–1697
  85. Arriagada R, Le MG, Contesso G, Guinebretiere JM, Rochard F, Spielmann M. Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer. Ann Oncol. 2002;13:1404–1413
  86. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–2106
  87. Kroman N, Holtveg H, Wohlfahrt J, Jensen MB, Mouridsen HT, Blichert-Toft M, et al. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer. 2004;100:688–693
  88. de Bock GH, van der Hage JA, Putter H, Bonnema J, Bartelink H, van de Velde CJ. Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer. 2006;42:351–356
  89. van der Leest M, Evers L, van der Sangen MJ, Poortmans PM, van de Poll-Franse LV, Vulto AJ, et al. The safety of breast-conserving therapy in patients with breast cancer aged < or = 40 years. Cancer. 2007;109:1957–1964
  90. Beadle BM, Woodward WA, Tucker SL, Outlaw ED, Allen PK, Oh JL, et al. Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys. 2009;73:734–744
  91. Jobsen JJ, van der Palen J, Ong F, Meerwaldt JH. The value of a positive margin for invasive carcinoma in breast-conservative treatment in relation to local recurrence is limited to young women only. Int J Radiat Oncol Biol Phys. 2003;57:724–731
  92. Hwang ES, Samli B, Tran KN, Rosen PP, Borgen PI, Van Zee KJ. Volume of resection in patients treated with breast conservation for ductal carcinoma in situ. Ann Surg Oncol. 1998;5:757–763
  93. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol. 1994;12:888–894
  94. Zhou P, Recht A. Young age and outcome for women with early-stage invasive breast carcinoma. Cancer. 2004;101:1264–1274
  95. Cabioglu N, Hunt KK, Buchholz TA, Mirza N, Singletary SE, Kuerer HM, et al. Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer. 2005;104:20–29
  96. Lu WL, Jansen L, Post WJ, Bonnema J, Van de Velde JC, De Bock GH. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat. 2009;114:403–412
  97. Sigal-Zafrani B, Bollet MA, Antoni G, Savignoni A, Vincet-Salomon A, Pierga JY, et al. Are ipsilateral breast tumour invasive recurrences in young (< or = 40 years) women more aggressive than their primary tumours?. Br J Cancer. 2007;97:1046–1052
  98. Alpert TE, Kuerer HM, Arthur DW, Lannin DR, Haffty BG. Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation. Int J Radiat Oncol Biol Phys. 2005;63:845–851
  99. Trombetta M, Julian T, Bhandari T, Werts ED, Miften M, Parda D. Breast conservation surgery and interstitial brachytherapy in the management of locally recurrent carcinoma of the breast: the Allegheny General Hospital experience. Brachytherapy. 2008;7:29–36
  100. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328–2335
  101. McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001;19:3938–3943
  102. Lostumbo L, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2004;CD002748
  103. Liebens FP, Carly B, Pastijn A, Rozenberg S. Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer. 2007;43:238–257
  104. Alm El-Din MA, Feng JK, Taghian AG. Lumpectomy and partial breast irradiation for early-stage breast cancer following mantle irradiation for Hodgkin's lymphoma. Nat Clin Pract Oncol. 2008;5:426–429
  105. Chadha M, Yoon H, Feldman S, Shah N, Moore E, Harrison LB. Partial breast brachytherapy as the primary treatment for breast cancer diagnosed after mantle radiation therapy for Hodgkin's disease. Am J Clin Oncol. 2009 March 20;[Epub ahead of print]
  106. Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25:5203–5209
  107. Tuttle TM, Jarosek S, Habermann EB, Arrington A, Abraham A, Morris TJ, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009;27:1362–1367
  108. Lee CN, Foster RD. Breast reconstruction after mastectomy in young women. Breast Dis. 2005;23:47–52
  109. Baildam AD. Breast reconstruction—state of the art. Breast. 2006;15(Suppl 2):S27–S30
  110. Cunnick GH, Mokbel K. Skin-sparing mastectomy. Am J Surg. 2004;188:78–84
  111. Allweis TM, Boisvert ME, Otero SE, Perry DJ, Dubin NH, Priebat DA. Immediate reconstruction after mastectomy for breast cancer does not prolong the time to starting adjuvant chemotherapy. Am J Surg. 2002;183:218–221
  112. Foster RD, Esserman LJ, Anthony JP, Hwang ES, Do H. Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma. Ann Surg Oncol. 2002;9:462–466
  113. Kronowitz SJ, Robb GL. Breast reconstruction with postmastectomy radiation therapy: current issues. Plast Reconstr Surg. 2004;114:950–960
  114. Carlson GW, Page AL, Peters K, Ashinoff R, Schaefer T, Losken A. Effects of radiation therapy on pedicled transverse rectus abdominis myocutaneous flap breast reconstruction. Ann Plast Surg. 2008;60:568–572
  115. Foster RD, Hansen SL, Esserman LJ, Hwang ES, Ewing C, Lane K, et al. Safety of immediate transverse rectus abdominis myocutaneous breast reconstruction for patients with locally advanced disease. Arch Surg. 2005;140:196–198
  116. McCormick B, Wright J, Cordiero P. Breast reconstruction combined with radiation therapy: long-term risks and factors related to decision making. Cancer J. 2008;14:264–268
  117. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717
  118. Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol. 2005;23:5166–5170
  119. Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355:1851–1862
  120. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–983
  121. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008;26:44–53
  122. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–2313
  123. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–1439
  124. Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol. 2009;27:1177–1183
  125. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672
  126. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684
  127. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778–785
  128. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757
  129. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53
  130. Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369:1711–1723
  131. Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2001;345:1378–1387
  132. Romestaing P, Lehingue Y, Carrie C, Coquard R, Montbarbon X, Ardiet JM, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol. 1997;15:963–968
  133. Cuzick J, Stewart H, Peto R, Baum M, Fisher B, Host H, et al. Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep. 1987;71:15–29
  134. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005;6:557–565
  135. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy (Danish Breast Cancer Cooperative Group 82b Trial). N Engl J Med. 1997;337:949–955
  136. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–1648
  137. Ragaz J, Olivotto IA, Spinelli JJ, Philips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97
  138. Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1539–1569
  139. National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdfAccessed March 30, 2009
  140. Jagsi R, Raad RA, Goldberg S, Suliivan T, Michaelson J, Powell SN, et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2005;62:1035–1039
  141. Litton JK, Theriault RL, Gonzalez-Angulo AM. Breast cancer diagnosis during pregnancy. Womens Health. 2009;5:243–249
  142. Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. Arch Surg. 2003;138:91–98
  143. Vetto JT. Breast cancer during pregnancy. In:  Khatri VP editors. Clinical Scenarios in Surgical Oncology. Philadelphia: Lippincott Williams & Wilkins; 2006;p. 241–244
  144. Petrek J. Breast cancer during pregnancy. Cancer. 1994;74(Suppl 1):518–527
  145. Berry D, Theriault R, Holmes F, Parisi VM, Booser DJ, Singletary SE, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol. 1999;17:855–861
  146. Spanheimer PM, Graham MM, Sugg SL, Scott-Conner CE, Weigel RJ. Measurement of uterine radiation exposure from lymphoscintigraphy indicates safety of sentinel lymph node biopsy during pregnancy. Ann Surg Oncol. 2009;16:1143–1147
  147. Cragan JD. Teratogen update: methylene blue. Teratology. 1999;60:42–48
  148. Khera SY, Kiluk JV, Hasson DM, Meade TL, Meyers MP, Dupont EL, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J. 2008;14:250–254
  149. Gonzalez-Angulo AM, Walters RS, Carpenter RJ, Ross MI, Perkins GH, et al. Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer. Clin Breast Cancer. 2004;5:317–319
  150. Melnick DM, Wahl WL, Dalton VK. Management of general surgical problems in the pregnant patient. Am J Surg. 2004;187:170–180
  151. Beral V, Bull D, Doll R, Peto R, Reeves G. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries. Lancet. 2004;363:1007–1016
  152. Kroman N, Jensen MB, Wohlfahrt J, Ejlertsen B. Pregnancy after treatment of breast cancer—a population-based study on behalf of Danish Breast Cancer Cooperative Group. Acta Oncol. 2008;47:545–549
  153. Huang E, Buchholz TA, Meric F, Krishnamurthy S, Mirza NQ, Ames FC, et al. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer. 2002;95:2059–2067
  154. Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer?. Surgery. 2002;132:620–626
  155. Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;24:2743–2749
  156. Singletary SE, Walsh G, Vauthey JN, Curley S, Sawaya R, Weber KL, et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist. 2003;8:241–251
  157. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197–2205
  158. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  159. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743
  160. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21:588–592
  161. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–2676
  162. Baucom DH, Porter LS, Kirby JS, Gremore TM, Keefe FJ. Psychosocial issues confronting young women with breast cancer. Breast Dis. 2005;23:103–113
  163. Screening (medicine). Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/Screening_%28medicine%29#Lead_time_biasAccessed April 6, 2009
  164. Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guideline in the adjuvant setting. J Clin Oncol. 2006;24:5091–5097
  165. Joseph E, Hyacinthe M, Lyman GH, Busch C, Demps L, Reintgen DS, et al. Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. Ann Surg Oncol. 1998;5:522–528
  166. de Bock GH, Bonnema J, van der Hage J, Kievit J, van de Velde CJ. Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. J Clin Oncol. 2004;22:4010–4018
  167. Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2005;CD001768
  168. Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007;356:1295–1303
  169. Saslow D, Boetes C, Burke W, Harms S, Leach MD, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75–89
  170. Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Fentiman IS, Robson ME, et al. Proceedings of the International Consensus Conference on Breast Cancer Risk, Genetics, & Risk Management, April 2007. Cancer. 2008;113:2627–2637
  171. Carlson RW, Anderson BO, Bensinger W, Cox CE, Davidson NE, Edge SB, et al. NCCN practice guidelines for breast cancer. Oncology. 2000;14:33–49
  172. Roche N. Follow-up after treatment for breast cancer in young women. Breast. 2006;15(Suppl 2):S71–S75
  173. Loprinzi CL, Wolf SL, Barton DL, Laack NN. Symptom management in premenopausal patients with breast cancer. Lancet Oncol. 2008;9:993–1001
  174. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363:453–455
  175. Dunn J, Steginga SK. Young women's experience of breast cancer: defining young and identifying concerns. Psychooncology. 2000;9:137–146
  176. Wenzel LB, Fairclough DL, Brady MJ, Cella D, Garrett KM, Kluhsman BC, et al. Age-related differences in the quality of life of breast carcinoma patients after treatment. Cancer. 1999;86:1768–1774
  177. Burwell SR, Case LD, Kaelin C, Avis NE. Sexual problems in younger women after breast cancer surgery. J Clin Oncol. 2006;24:2815–2821
  178. Fobair P, Stewart SL, Chang S, D'Onofrio C, Banks PJ, Bloom JR. Body image and sexual problems in young women with breast cancer. Psychooncology. 2006;15:579–594
  179. Schover LR. Sexuality and body image in younger women with breast cancer. J Natl Cancer Inst Monogr. 1994;177–182
  180. Mor V, Malin M, Allen S. Age differences in the psychosocial problems encountered by breast cancer patients. J Natl Cancer Inst Monogr. 1994;191–197
  181. Avis NE, Crawford S, Manuel J. Quality of life among younger women with breast cancer. J Clin Oncol. 2005;23:3322–3330
  182. Gadducci A, Cosio S, Genazzani AR. Ovarian function and childbearing issues in breast cancer survivors. Gynecol Endocrinol. 2007;23:625–631
  183. Maltaris T, Weigel M, Mueller A, Schmidt M, Seufert R, Fischl F, et al. Cancer and fertility preservation: fertility preservation in breast cancer patients. Breast Cancer Res. 2008;10:206
  184. Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: “healthy mother effect.”. Am J Obstet Gynecol. 1994;170:818–823
  185. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006;24:5769–5779
  186. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365–2370
  187. Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007;30:126–132
  188. Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005;104:1575–1579
  189. Han HS, Ro J, Lee KS, Nam BH, Seo JA, Lee DH, et al. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat. 2009;115:335–342
  190. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist. 2006;11:422–434
  191. Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril. 2006;86:70–80
  192. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23:4347–4353
  193. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26:2630–2635

PII: S0011-3840(09)00104-X

doi: 10.1067/j.cpsurg.2009.07.002

Current Problems in Surgery
Volume 46, Issue 12 , Pages 944-1004 , December 2009

Article Tools